Breast Cancer Panel
Breast cancer is the most commonly diagnosed cancer in U.S. women (~240,000 new cases/year). Breast cancer is heterogeneous with different tumor subtypes that are histologically similar but respond differently to therapy. Identifying the biological mechanisms of breast cancer can help to predict the behavior of the tumor. The Breast Cancer Panel is a series of tests that aid a physician in the diagnosis of breast cancer and help guide a physician in their treatment of a patient with this disease. Each of the assays gives information to the physician that will help make prognostic decisions on the staging and development of treatment regimens. The assays contained in this panel include Breast Cancer Antigen, CA 15-3, Epidermal Growth Factor Receptor, HER-2/neu, and Estrogen Receptor and Progesterone Receptor. Additional assays may be included in the Breast Cancer Panel, depending on the testing laboratory and the needs of individual physicians.
Cancer Antigen 15-3 (CA 15-3): Cancer antigen CA 15-3 is normally produced in the cells of the breast. Overexpression of CA 15-3 is associated with metastatic breast cancer. CA 15-3 is tested using blood and is used to stage and monitor breast cancer and to follow the course of treatment. When used in conjunction with other clinical and diagnostic procedures, serial testing for CA 15-3 cancer antigen is useful for monitoring the course of disease and therapy in metastatic breast cancer patients, and for detection of recurrence. In patients with known metastases, a reduction in CA 15-3 levels indicates a good response to treatment, while increasing levels indicate resistance to therapy and progressive disease. CA 15-3 is not sensitive or specific enough to be considered useful as a tool for cancer screening. It can be elevated in cancers of the lung, pancreas, liver, colon, and female Mullerian tract. It has been used as an approximation of the severity of breast cancer.
Human Epidermal Growth Factor Receptor 2 (HER-2/neu): Human Epidermal Growth Factor Receptor 2 or HER-2/neu is a biomarker associated with breast cancer. It is a member of the Epidermal Growth Factor Receptor (EGFR) family of proteins. HER-2/neu is encoded by the ERBB2 gene and influences cell growth and division activity. Two copies of the gene are found within normal healthy breast tissue. Abnormal cancerous cells may contain more than two copies of the HER-2 gene and produce the associated protein in excess. The excess protein causes the cells to multiply faster than normal. HER-2 positive results indicate that the mutation of the HER-2 gene is most likely one of the causative factors of the cancer. This mutation is somatic. Conversely, HER-2 negative status indicates that the HER-2 gene is not involved in the proliferation of the cancer. Some treatments of breast cancer can be prescribed for patients by evaluating the HER-2 protein production. Certain therapies target the HER-2 pathway and can be used to target tumors of patients that have a positive result for HER-2/neu analysis. HER-2/neu evaluations can also help physicians predict the outcome for patients. Because HER-2/neu positive patients have adverse outcome, targeting effective treatment is essential.
Estrogen and Progesterone Receptor: Estrogen and Progesterone are often found to drive the development of breast cancer. Estrogen is the hormone responsible most often for stimulating breast cancer, and less often, progesterone. Positive cancer cells have estrogen and progesterone receptors in the nucleus. Patients whose cancers are ER and/or PR positive often benefit from anti-estrogen therapy with agents such as Tamoxifen. About a third of patients with ER positive metastatic breast cancer will show benefit from anti-estrogen therapy. ER negative patients almost never benefit from anti-estrogen therapy. Thus, ER expression is one of the most important factors in determining response to endocrine therapy. Estrogen/progesterone receptor assays are performed on malignant breast tissue to assess prognosis and to determine which patients will most likely benefit from chemotherapy or hormonal manipulation.
- Breast Cancer Antigen CA 15-3 (CA 15-3): Used to manage breast cancer, monitor the course of disease and therapy in metastatic breast cancer patients.
- Epidermal Growth Factor Receptor: Used to determine eligibility for therapies targeting epidermal growth factor receptor (EGFR), predicts patient outcome in patients treated with EGFR antagonists and disease monitoring.
- HER-2 /neu: Used to aid in the evaluation of breast cancer and management of disease therapy.
- ER and PR Assay: Used to aid in the differential diagnosis, disease management, therapy and prediction of patient response (to hormonal therapy) in breast cancer. Also prognostic for patient response to adjuvant endocrine therapy.
- *Breast Cancer Antigen CA 15-3 (CA 15-3):* Elevated in metastatic breast cancer, cirrhosis, benign breast disorders; low level elevations are seen in pancreatic cancer and very low levels might be present in apparently healthy individuals.
- *Epidermal Growth Factor Receptor:* Positive (FISH) results are prognostic with regard to response to EGFR-targeted therapies. Negative (FISH) results are associated with a greater likelihood of drug resistance. Positive (IHC) are associated with patients with NSCLC and results predict response to certain targeted therapies. Negative (IHC) may be predictive of drug resistance.
- *HER-2 /neu:* Positive IHC for protein overexpression (3 or 4
- ) is highly correlated with gene amplification and indicates therapy with anti-Her2 agents such as Herceptin would be beneficial. Positive gene amplification in cases of equivocal IHC also indicates anti-Her2 therapy would be beneficial and gives prognostic information for treatment in breast cancer.
- *ER and PR Assay:* Receptor-positive tumors typically have a better prognosis with longer interval to disease progression, better overall survival than patients with receptor-negative tumors.
Breast Cancer Antigen CA 15-3 (CA 15-3): 0 - 30 U/mL
Epidermal Growth Factor Receptor: Negative for mutation analyzed
HER-2 /neu: Negative for amplification
ER and PR Assays: Negative <1%. Percentage and intensity of positive staining
Breast Cancer Antigen CA 15-3 (CA 15-3): Enzyme immunoassay.
Epidermal Growth Factor Receptor: Immunohistochemical Assay (IHC), Fluorescence In Situ Hybridization (FISH).
HER-2 /neu: IHC staining and FISH by manual or computer-aided methods.
ER and PR Assay: Immunohistochemical Assay (IHC).
- Breast Cancer Antigen CA 15-3 (CA 15-3): Serum or plasma
- Epidermal Growth Factor Receptor: Formalin-fixed, paraffin-embedded tumor tissue
- HER-2 /neu: Formalin-fixed, paraffin-embedded tumor tissue
- ER and PR Assays: Formalin-fixed, paraffin-embedded tumor tissue
- Eur J Obstet Gynecol Reprod Biol. 1999 Mar;83(1):67-75. [PMID: 10221613]
- Tumour Biol. 2002 Nov-Dec;23(6):315-23. [PMID: 12677089]
- Ann Clin Biochem. 1999 Sep;36 ( Pt 5):579-86. [PMID: 10505206]
- Br J Cancer. 1997;75(5):698-702. [PMID: 9043027]
- Eur J Cancer. 1992;29A(1):144-6. [PMID: 1445733]
- Cancer. 1991 Aug 1;68(3):574-82. [PMID: 2065278]
- Oncologist. 2002;7 Suppl 4:31-9. [PMID: 12202786]
- N Engl J Med. 2004 May 20;350(21):2129-39. [PMID: 15118073]
- Clin Lung Cancer. 2009 Jul;10(4):281-9. [PMID: 19632948]
- Oncogene. 2009 Aug;28 Suppl 1:S24-31. [PMID: 19680293]
- Curr Drug Targets. 2010 Jul;11(7):851-64. [PMID: 20388064]
- Mark M. Breast Cancer and HER2. Emedicine. 2009 June 30.
- J Clin Oncol. 2010 Jun 1;28(16):2784-95. [PMID: 20404251]
- J Clin Oncol. 2007; 25(33):5287-312. [PMID: 17954709]
- Clin Chem. 1996; 42(12); 1955-60. [PMID: 8969632]
- J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21. [PMID: 19755043]
- Mod Pathol. 2008 May;21 Suppl 2:S8-S15. [PMID: 18437174]
- Acta Oncol. 1988;27(1):1-19. Review. [PMID: 3284552]